ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-yearPurified Cortrophin® Gel net revenues of$ 101.9 million, an increase of 93.8% year-over-yearRecord quarterly adjusted non-GAAP EBITDA of $59.6 million, an increase of 69.8% year-over-yearDiluted GAAP income per share of$ 1.13 and record adjusted non-GAAP diluted earnings per share of $2.04Raised 2025 total net revenue guidance to$ 854.0 million to $873.0 million, adjusted non-GAAP EBITDA to$ 221.0 million to $228.0 million, ...